ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

Collaboration among trial sponsors can pool expertise and resources, potentially accelerating drug development and regulatory success. This study assessed whether collaborations between drug sponsors ...

Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors We queried ClinicalTrials.gov for all industry-sponsored, ...

Please provide your email address to receive an email when new articles are posted on . Adults with Cushing’s syndrome have a 78% higher risk for any cancer compared with controls. Cushing’s syndrome ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) ...

Experimental drugs for renal and other genitourinary cancers are more likely to be approved when pharmaceutical companies collaborate on the research, according to a study in JCO Oncology Practice.

An observational study found that erythropoiesis-stimulating agent (ESA) usage was associated with increased risk of malignancies in patients with chronic kidney disease (CKD) or end-stage renal ...

Men middle-aged and older routinely get blood tests for prostate-specific antigen, or PSA, to screen for prostate cancer. However, PSA testing has shortcomings: many men with elevated PSAs don't have ...